Compare State Street SPDR S&P Biotech ETF (XBI) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Clear Secure Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.35, while Clear Secure Inc trades at $46.25 (market cap $4.98B). The key difference: Clear Secure Inc pays a 1.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Clear Secure Inc nearer its low. Which is the better fit depends on your goals.
| XBI | YOU | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $164.28 | $62.36 |
52-Week Low | $86.92 | $29.61 |
Market Cap | — | $4.98B |
Enterprise Value | — | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
CLEAR Secure (YOU) trades at $46.16, down 9.86% in the past 24 hours, approaching key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating expectations at $0.49 per share versus $0.40 expected, driven by 66.66% gross margins and 90.29% ROE. Recent news highlights enterprise expansion including corporate membership launches and airport service investments.
Outlook remains positive with revenue growth accelerating to $1.0B in 2026 and analyst consensus leaning bullish (44% Buy ratings). Key risks include competitive pressure in identity verification and execution of new corporate initiatives. The current dip may present a buying opportunity for growth investors given strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
